<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Research in 2024 | ARSACS</title>
	<atom:link href="https://arsacs.com/fr/category/research-in-2024/feed/" rel="self" type="application/rss+xml" />
	<link>https://arsacs.com/fr</link>
	<description>Research That Heals</description>
	<lastBuildDate>Mon, 16 Mar 2026 22:16:54 +0000</lastBuildDate>
	<language>fr-CA</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	

<image>
	<url>https://arsacs.com/wp-content/uploads/2021/02/cropped-FAVICON-32x32.png</url>
	<title>Research in 2024 | ARSACS</title>
	<link>https://arsacs.com/fr</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>&#8220;Dimethyl Fumarate Tested on the ARSACS Mouse Model&#8221; &#8211; Drs. Justin Wolter &#038; Huaxia Wang</title>
		<link>https://arsacs.com/fr/dimethyl-fumarate-tested-on-the-arsacs-mouse-model-drs-justin-wolter-huaxia-wang/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Wed, 16 Oct 2024 16:45:07 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21444</guid>

					<description><![CDATA[This project, led by Drs. Justin Wolter and Huaxia Wang, aims to test the therapeutic potential of dimethyl fumarate (DMF) in the ARSACS mouse model. DMF is currently approved for the treatment of multiple sclerosis (MS), where it has been shown to reduce neuroinflammation, oxidative stress, and neuronal death. Additionally, DMF has been tested in [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph">This project, led by Drs. Justin Wolter and Huaxia Wang, aims to test the therapeutic potential of dimethyl fumarate (DMF) in the ARSACS mouse model. DMF is currently approved for the treatment of multiple sclerosis (MS), where it has been shown to reduce neuroinflammation, oxidative stress, and neuronal death. Additionally, DMF has been tested in preclinical models of other neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer’s disease, where it demonstrates promising neuroprotective effects. In our study, we will evaluate the therapeutic potential of DMF in the ARSACS mouse model, testing motor function and molecular markers of neuroinflammation, oxidative stress, and neurodegeneration. Successful results could pave the way for DMF-based treatments in future ARSACS clinical trials, and determine the utility of specific biomarkers in tracking ARSACS progression.</p>



<p class="wp-block-paragraph"><strong>&nbsp;</strong>Grant: $120,796</p>



<p class="has-text-align-left wp-block-paragraph">Durée : un an</p>



<p class="wp-block-paragraph">Contact :</p>



<div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex">
<div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow">
<div class="wp-block-media-text is-stacked-on-mobile" style="grid-template-columns:40% auto"><figure class="wp-block-media-text__media"><img decoding="async" src="https://arsacs.com/wp-content/uploads/2024/10/Wolter-headshot-2-683x1024.jpeg" alt="" class="wp-image-21470 size-full"/></figure><div class="wp-block-media-text__content">
<p class="wp-block-paragraph">University of Wisconsin Biotechnology Center<br>425 Henry Mall, Genetics Biotech Center, 5302A<br>Madison, Wisconsin, USA<br>53706</p>



<p class="wp-block-paragraph">hwang2493@wisc.edu<br>wolter4@wisc.edu</p>
</div></div>
</div>



<div class="wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow"></div>
</div>



<figure class="wp-block-image size-full is-resized"><img fetchpriority="high" decoding="async" width="256" height="256" src="https://arsacs.com/wp-content/uploads/2024/10/people-huaxia-headshot-6.jpeg" alt="" class="wp-image-21494" style="width:164px;height:auto" srcset="https://arsacs.com/wp-content/uploads/2024/10/people-huaxia-headshot-6.jpeg 256w, https://arsacs.com/wp-content/uploads/2024/10/people-huaxia-headshot-6-150x150.jpeg 150w" sizes="(max-width: 256px) 100vw, 256px" /></figure>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“ Modélisation de l’ARSACS chez l’homme à l’aide d’organoïdes cérébelleux dérivés de cellules iPS ” – Dr Esther Becker</title>
		<link>https://arsacs.com/fr/modelling-arsacs-in-human-in-ipsc-derived-cerebellar-organoids-dr-esther-becker-3/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:18:41 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21112</guid>

					<description><![CDATA[This project aims to create three-dimensional disease models called ‘organoids’ using induced pluripotent stem cells (iPSCs) from ARSACS patients. Human iPSCs are obtained from individuals’ skin cells by a process known as reprogramming and resemble stem cells present in the developing human embryo that are capable of turning into any cell type in the body. [...]]]></description>
										<content:encoded><![CDATA[<p>This project aims to create three-dimensional disease models called ‘organoids’ using induced pluripotent stem cells (iPSCs) from ARSACS patients. Human iPSCs are obtained from individuals’ skin cells by a process known as reprogramming and resemble stem cells present in the developing human embryo that are capable of turning into any cell type in the body. Coaxing these iPSCs into brain cells allows us to study living human nerve cells from affected patients in the laboratory and to recapitulate early events that lead to disease. This innovative method will allow us to better understand why it is the Purkinje cells in the cerebellum that are particularly affected in ARSACS. We propose to produce cerebellar organoids from ARSACS iPSCs and compare these to organoids generated from healthy controls. This will shed light on the molecular and cellular processes that go awry in the ARSACS cerebellum and that might be amenable to therapeutic correction. In the long term, we hope that cerebellar organoid models for ARSACS will help to develop better treatments for this disease.</p>
<p><strong> </strong></p>
<p>Grant: $66,195</p>
<p style="text-align: left;">Duration: first year of a 2 year project</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="alignnone  wp-image-21115" src="https://arsacs.com/wp-content/uploads/2024/08/Esther_Becker-300x246.jpg" alt="" width="241" height="198" /></p>
<p>Dre Esther Becker</p>
<p>University of Oxford<br />Nuffield Department of Clinical Neurosciences<br />Kavli Institute for Nanoscience Discovery<br />Dorothy Crowfoot Hodgkin Building<br />Oxford OX1 3QU<br />United Kingdom<br />esther.becker@ndcn.ox.ac.uk</p>
<p style="text-align: center;"> </p>






<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“ Détermination de la structure de la saccine ” – Dr Walid Houry</title>
		<link>https://arsacs.com/fr/structural-determination-of-sacsin-dr-walid-houry-3-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:16:58 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21095</guid>

					<description><![CDATA[  Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a non-treatable neurodegenerative genetic disorder of early childhood and adulthood. When first reported in 1978, ARSACS was described as a unique form of ataxia, accompanied with motor speech anomalies, muscle wasting phenotypes, and peripheral nerve complications. ARSACS symptoms worsen in adulthood, with most individuals losing the [...]]]></description>
										<content:encoded><![CDATA[<p> </p>
<p>Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a non-treatable neurodegenerative genetic disorder of early childhood and adulthood. When first reported in 1978, ARSACS was described as a unique form of ataxia, accompanied with motor speech anomalies, muscle wasting phenotypes, and peripheral nerve complications. ARSACS symptoms worsen in adulthood, with most individuals losing the ability to walk by the age of 50. Genetic studies have established that ARSACS is caused by mutations in Sacsin – a protein whose biology is poorly known. Current research suggests that Sacsin supports cytoskeletal and mitochondrial organization. To shed light on Sacsin function, one needs to study Sacsin structure in both native and mutated states. However, no published research has described the purification of Sacsin protein for <em>in vitro</em> and structural investigations. This technical gap in research is due to the large size of Sacsin (~520 kDa). Our laboratory has now solved this issue. We have carried out early <em>in vitro</em> characterizations of Sacsin, and we are working to obtain its three-dimensional (3D) structure using cryogenic electron microscopy. Our current focus is to increase the resolution of our 3D model and, subsequently, begin <em>in silico</em> drug screening.</p>
<p>Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="alignleft  wp-image-6572" src="https://arsacs.com/wp-content/uploads/2021/02/Walid_Houry_University_Toronto-e1606423339816.jpg" alt="" width="200" height="236" /></p>
<p>Dr. Walid A. Houry, Department of Biochemistry</p>
<p>Faculté de médecine Temerty de l'Université de Toronto<br />661 University Avenue,MaRS Centre, West Tower, Room 1612</p>
<p>Toronto, ON, Canada M5G 1M1</p>
<p> <a href="mailto:walid.houry@utoronto.ca">walid.houry@utoronto.ca</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Targeting Cav2.1 to recover firing defects and degeneration of Purkinje neurons in ARSACS ” &#8211; Dr. Francesca Maltecca</title>
		<link>https://arsacs.com/fr/targeting-cav2-1-to-recover-firing-defects-and-degeneration-of-purkinje-neurons-in-arsacs-dr-francesca-maltecca/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:15:31 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21143</guid>

					<description><![CDATA[A central theme in cerebellar ataxia is mutations in genes encoding calcium regulatory genes, highlighting the selective vulnerability of Purkinje neurons to alteration of calcium fluxes. We have recently demonstrated that the Voltage-Gated Calcium Channel (VGCC) Cav2.1 is increased in amount at the Purkinje neurons’ plasma membrane in the Sacs-/- mouse, and this results in [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph">A central theme in cerebellar ataxia is mutations in genes encoding calcium regulatory genes, highlighting the selective vulnerability of Purkinje neurons to alteration of calcium fluxes. We have recently demonstrated that the Voltage-Gated Calcium Channel (VGCC) Cav2.1 is increased in amount at the Purkinje neurons’ plasma membrane in the <em>Sacs<sup>-/-</sup></em> mouse, and this results in a striking 30% augment in Cav2.1-mediated calcium currents as compared to controls. We also found that Cav2.1 overactivation is functionally connected with the reduced pacemaking firing activity of <em>Sacs<sup>-/-</sup></em> Purkinje neurons. Based on these findings, the project involves a parallel screening of non-selective inhibitors already in use in the clinic to validate Cav2.1 as a target, and a <em>de novo</em> screening of potent and selective Cav2.1 inhibitors. The latter may represent a remarkable breakthrough due to the potential therapeutic relevance in the treatment of ARSACS and also other Cav2.1-related diseases.</p>


<p class="PANormalLevelIA" style="text-align: justify;">Subvention : $100 000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p style="text-align: left;"><img loading="lazy" decoding="async" class="size-full wp-image-11103 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/DrFrancescaMaltecca-150x150-2.jpg" alt="" width="150" height="150" /></p>
<p>Dre Francesca Maltecca</p>
<p>Ospedale San Raffaele</p>
<p>Via Olgettina 58,20132, Milan, Italy  </p>
<p> <a href="mailto:maltecca.francesca@hsr.it">maltecca.francesca@hsr.it</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Therapeutic Approaches for ARSACS&#8221;- Drs. Benoit Gentil and Heather Durham</title>
		<link>https://arsacs.com/fr/therapeutic-approaches-for-arsacs-drs-benoit-gentil-and-heather-durham-3/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:13:30 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21137</guid>

					<description><![CDATA[ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors. The challenge of gene replacement therapies in ARSACS resides in the size [...]]]></description>
										<content:encoded><![CDATA[<p>ARSACS is characterised by the lack of sacsin expression, and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors. The challenge of gene replacement therapies in ARSACS resides in the size of the sacsin coding sequence which is not compatible with current vectors used for gene therapies. Using our expertise in sacsin domains functions, we have designed a minigene to be used for the resorption of molecular biomarker of the disease. Our laboratory is moving forward the development of replacement therapies. We have generated a vector for gene therapy and are moving forward our project to determine its efficiency in modifying the course of ARSACS pathology in mice models. Our project at the preclinical stage also received support from NeuroSphere, the McGill platform dedicated to innovation and partnership in neuroscience research, through the ACCELERATE partnership between Neurosphere and the ARSACS Foundation ($200,000). This convergence of support from the Foundation and NeuroSphere will advance investigations into the development and feasibility of gene therapy for ARSACS.</p>
<p>Subvention : $100 000</p>
<p>Duration: second year of a 2 year project</p>
<p>Contacts<br /><img loading="lazy" decoding="async" class="alignleft  wp-image-3643" src="https://arsacs.com/wp-content/uploads/2021/02/Durham_Benoit_Nov_2017-150x150-2.jpg" alt="" width="199" height="199" /></p>
<p>Le Dr Benoit Gentil  et le Dr Heather Durham</p>
<p><span style="font-size: revert;">Département de kinésiologie et d'éducation physique, Université McGill </span></p>
<p>475 Pine Avenue West,   room 210,  Montreal (Québec)  H2W 1S4</p>
<p> heather.durham@mcgill.ca, <span style="font-size: revert;"> benoit.gentil@mcgill.ca</span></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“ Développement de modèles murins conditionnels et de nouvelles approches thérapeutiques pour l’ARSACS ” – Dr Stefan Strack</title>
		<link>https://arsacs.com/fr/developing-conditional-mouse-models-and-new-approaches-to-treating-arsacs-dr-stefan-strack-3/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:11:30 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21098</guid>

					<description><![CDATA[Mouse models are invaluable for studying disease mechanisms and ultimately treatment. The Sacs knock-out (KO) mouse is a faithful model of ARSACS, displaying ataxia, muscle weakness, cerebellar degeneration, and, as we have recently shown, learning and memory deficits. With this proposal, we seek to pharmacologically rescue motor- and cognitive phenotypes in the Sacs KO model [...]]]></description>
										<content:encoded><![CDATA[<p>Mouse models are invaluable for studying disease mechanisms and ultimately treatment. The <em>Sacs</em> La souris « knock-out » (KO) constitue un modèle fidèle de l'ARSACS, présentant une ataxie, une faiblesse musculaire, une dégénérescence cérébelleuse et, comme nous l'avons récemment démontré, des troubles de l'apprentissage et de la mémoire. Dans le cadre de cette proposition, nous cherchons à restaurer par voie pharmacologique les phénotypes moteurs et cognitifs chez la <em>Sacs</em> KO model of ARSACS with a drug that raises levels of a second messenger (cAMP) in the brain. This drug is currently in preclinical development for other neurological disorders and could therefore be rapidly repurposed for ARSACS treatment. Indeed, our pilot results show that this drug improves spatial memory of <em>Sacs</em> KO mice. Second, we propose to develop gene therapy for ARSACS. To this end, we will develop a novel, high-capacity viral vector to express the huge Sacsin protein in the brain of <em>Sacs</em> KO mice.  Third, we will begin to develop and characterize a conditional <em>Sacs</em> KO model to pinpoint where and when <em>Sacs</em> loss-of-function causes the spectrum of ARSACS symptoms. While our drug studies are directly translational, both Aims 2 and 3 will generate invaluable reagents that will be shared with the wider ARSACS research community in an effort to expedite therapies. </p>
<p><strong> </strong></p>
<p>Subvention : $100 000</p>
<p style="text-align: left;">Durée : un an</p>
<p>Contact :</p>
<p><img decoding="async" class="alignleft" src="https://arsacs.com/wp-content/uploads/2023/09/Strack.jpg" /></p>
<p>Dr Stefan Strack, Département des neurosciences et de pharmacologie</p>
<p>Faculté de médecine Carver de l'Université de l'Iowa</p>
<p>2-452 BSB, 51 Newton Rd., Iowa City, IA 52242<br /><span class="gI"><span class="qu" tabindex="-1" role="gridcell" translate="no"><span class="go">stefan-strack@uiowa.edu</span></span></span></p>
<p style="text-align: center;"> </p>






<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Retinal pigment epithelium (RPE) cell system to uncover the molecular mechanisms of ARSACS – related retinal effects” &#8211; Drs. Daniele Galatolo and Giulia De Riso</title>
		<link>https://arsacs.com/fr/retinal-pigment-epithelium-rpe-cell-system-to-uncover-the-molecular-mechanisms-of-arsacs-related-retinal-effects-drs-daniele-galatolo-et-giulia-de-riso/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:09:41 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21102</guid>

					<description><![CDATA[The overall aim of this project is to identify the potential role of DNA methylation changes as biomarker of ARSACS progression. We previously demonstrated that patients affected by ARSACS showed changes in DNA methylation pattern, indicating that epigenetics might have a role in disease pathogenesis. These findings encouraged us to get deeper in this field [...]]]></description>
										<content:encoded><![CDATA[The overall aim of this project is to identify the potential role of DNA methylation changes as biomarker of ARSACS progression. We previously demonstrated that patients affected by ARSACS showed changes in DNA methylation pattern, indicating that epigenetics might have a role in disease pathogenesis. These findings encouraged us to get deeper in this field and hypothesize that changes in DNA methylation could constitute a biomarker of disease progression. To achieve our aim, we will analyze the most biologically significant regions of the human methylome in a large group of patients in the context of patients' clinical history and disease progression.

Grant: $49,500

Duration : one year

Contact:

<img loading="lazy" decoding="async" class="wp-image-15770 alignleft" src="https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo-201x300.jpg" alt="" width="182" height="272" srcset="https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo-201x300.jpg 201w, https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo.jpg 408w" sizes="(max-width: 182px) 100vw, 182px" />

Dr. Daniele Galatolo

Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit

IRCCS Stella Maris Foundation

via dei Giacinti 2,

56128 Calambrone (Pisa) - Italy

<a href="mailto:daniele.galatolo@fsm.unipi.it">daniele.galatolo@fsm.unipi.it</a>
<p style="text-align: left;">Dr Giulia De Rosi</p>
<p style="text-align: left;">Co-project investigator</p>
<img loading="lazy" decoding="async" class="wp-image-21106 alignleft" src="https://arsacs.com/wp-content/uploads/2024/08/Giulia-De-Riso--150x150.jpg" alt="" width="192" height="192" /><span id="more-21102"></span>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Elucidating mechanisms underlying motor coordination rescue in a mouse model of ARSACS&#8221; &#8211; Drs. Alanna Watt &#038; Anne McKinney</title>
		<link>https://arsacs.com/fr/elucidating-mechanisms-underlying-motor-coordination-rescue-in-a-mouse-model-of-arsacs-drs-alanna-watt-anne-mckinney-4/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:08:20 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21139</guid>

					<description><![CDATA[A compléter Grant: $213,000 Duration: second year of a 2 year project Contact: Dr. Alanna Watt, Department of Biology McGill University, Bellini Life Science  Building, room 2653469 Sir William Osler, Montreal, Quebec Canada H3G 0B1  alanna.watt@mcgill.ca Dr. Anne McKinney, Department of Pharmacology and Therapeutics  McGill University Bellini Life Science Building, room 1673469 Sir William Osler, Montreal, [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<p>A compléter</p>
<p>Grant: $213,000</p>
<p style="text-align: left;">Duration: second year of a 2 year project</p>
<p>Contact :<br /><img loading="lazy" decoding="async" class="wp-image-132 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/watt-1-150x150-2.jpg" alt="Dre Alanna Watt" width="198" height="198" /></p>
<p style="text-align: center;">Dr. Alanna Watt, <span style="font-size: 10.5pt; font-family: 'Open Sans',sans-serif; color: #666666;">Department of Biology</span></p>
<p style="text-align: center;">McGill University, Bellini Life Science  Building, room 265<br />3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1 <br /><a href="mailto:alanna.watt@mcgill.ca"> alanna.watt@mcgill.ca</a></p>
<p style="text-align: center;"><img loading="lazy" decoding="async" class="wp-image-11142 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Anne-McKinney-150x150-2.jpg" alt="" width="201" height="201" /></p>
<p style="text-align: center;">Dr. Anne McKinney, Department of Pharmacology and Therapeutics </p>
<p style="text-align: center;">McGill University Bellini Life Science Building, room 167<br />3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1<br /><a href="mailto:anne.mckinney@mcgill.ca"> anne.mckinney@mcgill.ca</a></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“ Comprendre les anomalies du transport dans l’ARSACS afin d’identifier des cibles thérapeutiques pour cette maladie ” – Dr Paul Chapple</title>
		<link>https://arsacs.com/fr/understanding-trafficking-defects-in-arsacs-to-identify-therapeutic-targets-for-disease-dr-paul-chapple-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:06:55 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21093</guid>

					<description><![CDATA[Our previous research has shown that the ARSACS protein sacsin is essential for proper trafficking of other proteins to the cell surface. In the absence of sacsin this process is disrupted, which may lead to the aberrant localisation of key neuronal proteins, stopping them working properly and contributing to disease. This project aims to use [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph"></p>


<p>Our previous research has shown that the ARSACS protein sacsin is essential for proper trafficking of other proteins to the cell surface. In the absence of sacsin this process is disrupted, which may lead to the aberrant localisation of key neuronal proteins, stopping them working properly and contributing to disease. This project aims to use cellular models and analysis of existing human brain gene expression data to better understand which proteins rely on sacsin for normal traffic and function. We will also further investigate the mechanisms by which sacsin loss alters protein trafficking and use advanced computational methods to identify drugs that could potentially correct the trafficking issues. The focus here will be existing drugs that can be repurposed to treat ARSACS.</p>
<p>Grant: $67,900</p>
<p>Duration: first  year of a 3 year project</p>
<p>Contact :</p>
<p style="text-align: left;"><img loading="lazy" decoding="async" class="wp-image-17311  alignleft" src="https://arsacs.com/wp-content/uploads/2022/07/Paul_chapple_2022_-Research-report_website-150x150.jpg" alt="" width="165" height="165" /></p>
<p style="text-align: left;">Dr. Paul Chapple , Faculty of Medicine and Dentistry<br />Queen Mary University of London<br />London UL<br /><a href="mailto:j.p.chapple@qmul.ac.uk">j.p.chapple@qmul.ac.uk</a></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Avatar mouse model of a new genetic variant of ARSACS detected in Uruguay&#8221; &#8211; Dr. Martina Crispo Benedetto</title>
		<link>https://arsacs.com/fr/avatar-mouse-model-of-a-new-genetic-variant-of-arsacs-detected-in-uruguay-dr-martina-crispo-benedetto/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Sat, 31 Aug 2024 16:05:05 +0000</pubDate>
				<category><![CDATA[Research in 2024]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=21148</guid>

					<description><![CDATA[“Our goal is to generate an AVATAR mouse model to reproduce the heterozygous compound alteration of a Uruguayan-child, in South America. Using the CRISPR/Cas technology we will generate a frameshift SACS variant mouse line, reproducing the father’s modification and other mouse line with a missense PRO2369LEU VARIANT for the mother. Obtaining this grant allows us [...]]]></description>
										<content:encoded><![CDATA[<p>“Our goal is to generate an AVATAR mouse model to reproduce the heterozygous compound alteration of a Uruguayan-child, in South America. Using the CRISPR/Cas technology we will generate a frameshift SACS variant mouse line, reproducing the father’s modification and other mouse line with a missense PRO2369LEU VARIANT for the mother. Obtaining this grant allows us to validate the animal model and initiate pre-clinical studies of this disease in our country in a near future.”</p>
<p><strong>New this year - Seed Grant Project ! <br /></strong></p>
<p> Subvention : $25 000</p>
<p style="text-align: left;">Durée : un an</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="alignnone wp-image-21151 size-medium" src="https://arsacs.com/wp-content/uploads/2024/08/Martina-Crispo-300x193.jpg" alt="" width="300" height="193" /></p>
<p>From left to right: Geraldine Schlapp, Martina Crispo, María Noel Meikle, Jorge Luis Pórfido</p>
<p>Dr. Martina Crispo Benedetto</p>
<p>Mataojo 2020<br />Institut Pasteur of Montevideo  <br />Montevideo, Uruguay<br />crispo@pasteur.edu.uy</p>
<p style="text-align: center;"> </p>






<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>